Suppression of Ras-stimulated transformation by the JNK signal transduction pathway
| dc.contributor.author | Kennedy, Norman J. | |
| dc.contributor.author | Sluss, Hayla Karen | |
| dc.contributor.author | Jones, Stephen N. | |
| dc.contributor.author | Bar-Sagi, Dafna | |
| dc.contributor.author | Flavell, Richard A. | |
| dc.contributor.author | Davis, Roger J. | |
| dc.date | 2022-08-11T08:10:03.000 | |
| dc.date.accessioned | 2022-08-23T16:53:11Z | |
| dc.date.available | 2022-08-23T16:53:11Z | |
| dc.date.issued | 2003-03-12 | |
| dc.date.submitted | 2008-07-15 | |
| dc.identifier.citation | <p>Genes Dev. 2003 Mar 1;17(5):629-37. <a href="http://dx.doi.org/10.1101/gad.1062903">Link to article on publisher's site</a></p> | |
| dc.identifier.issn | 0890-9369 (Print) | |
| dc.identifier.doi | 10.1101/gad.1062903 | |
| dc.identifier.pmid | 12629045 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/42216 | |
| dc.description.abstract | The c-Jun NH(2)-terminal kinase (JNK) phosphorylates and activates members of the activator protein-1 (AP-1) group of transcription factors and is implicated in oncogenic transformation. To examine the role of JNK, we investigated the effect of JNK deficiency on Ras-stimulated transformation. We demonstrate that although JNK does play a role in transformation in vitro, JNK is not required for tumor development in vivo. Importantly, the loss of JNK expression resulted in substantial increases in the number and growth of tumor nodules in vivo. Complementation assays demonstrated that this phenotype was caused by JNK deficiency. These data demonstrate that, in contrast to expectations, the normal function of JNK may be to suppress tumor development in vivo. This conclusion is consistent with the presence in human tumors of loss-of-function mutations in the JNK pathway. | |
| dc.language.iso | en_US | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=12629045&dopt=Abstract">Link to Article in PubMed</a></p> | |
| dc.relation.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC196007/ | |
| dc.subject | Animals | |
| dc.subject | Cell Line | |
| dc.subject | Cell Transformation, Neoplastic | |
| dc.subject | Fibroblasts | |
| dc.subject | JNK Mitogen-Activated Protein Kinases | |
| dc.subject | Male | |
| dc.subject | Mice | |
| dc.subject | Mice, Nude | |
| dc.subject | Mitogen-Activated Protein Kinases | |
| dc.subject | Neoplasms, Experimental | |
| dc.subject | Signal Transduction | |
| dc.subject | ras Proteins | |
| dc.subject | Life Sciences | |
| dc.subject | Medicine and Health Sciences | |
| dc.title | Suppression of Ras-stimulated transformation by the JNK signal transduction pathway | |
| dc.type | Journal Article | |
| dc.source.journaltitle | Genes and development | |
| dc.source.volume | 17 | |
| dc.source.issue | 5 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/oapubs/583 | |
| dc.identifier.contextkey | 549012 | |
| html.description.abstract | <p>The c-Jun NH(2)-terminal kinase (JNK) phosphorylates and activates members of the activator protein-1 (AP-1) group of transcription factors and is implicated in oncogenic transformation. To examine the role of JNK, we investigated the effect of JNK deficiency on Ras-stimulated transformation. We demonstrate that although JNK does play a role in transformation in vitro, JNK is not required for tumor development in vivo. Importantly, the loss of JNK expression resulted in substantial increases in the number and growth of tumor nodules in vivo. Complementation assays demonstrated that this phenotype was caused by JNK deficiency. These data demonstrate that, in contrast to expectations, the normal function of JNK may be to suppress tumor development in vivo. This conclusion is consistent with the presence in human tumors of loss-of-function mutations in the JNK pathway.</p> | |
| dc.identifier.submissionpath | oapubs/583 | |
| dc.contributor.department | Department of Cell Biology | |
| dc.contributor.department | Department of Cancer Biology | |
| dc.contributor.department | Program in Molecular Medicine | |
| dc.contributor.department | Howard Hughes Medical Institute | |
| dc.source.pages | 629-37 |